ALB and cancer: Various inflammatory mediators such as tumor necrosis factor (TNF), which augments microvascular leakiness, along with interleukin-1 (IL-1) and interleukin-6 (IL-6), known to suppress albumin production, contribute to the observed decrease in serum albumin among cancer-afflicted individuals (37, 38).